A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection
| Autor: | Santa-Mariela Olivera-Ugarte, Marilène Bolduc, Marie-Ève Laliberté-Gagné, Léa-Jeanne Blanchette, Caroline Garneau, Maude Fillion, Pierre Savard, Isabelle Dubuc, Louis Flamand, Omar Farnòs, Xingge Xu, Amine Kamen, Mégan Gilbert, Henintsoa Rabezanahary, Martina Scarrone, Christian Couture, Mariana Baz, Denis Leclerc |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Mice
Inbred BALB C COVID-19 Vaccines SARS-CoV-2 Biomedical Engineering Pharmaceutical Science Medicine (miscellaneous) COVID-19 Bioengineering Antibodies Viral Antibodies Neutralizing Potexvirus Mice Molecular Medicine Animals Humans Nanoparticles General Materials Science Broadly Neutralizing Antibodies |
| Zdroj: | Nanomedicine : nanotechnology, biology, and medicine. 44 |
| ISSN: | 1549-9642 |
| Popis: | A vaccine candidate to SARS-CoV-2 was constructed by coupling the viral receptor binding domain (RBD) to the surface of the papaya mosaic virus (PapMV) nanoparticle (nano) to generate the RBD-PapMV vaccine. Immunization of mice with the coupled RBD-PapMV vaccine enhanced the antibody titers and the T-cell mediated immune response directed to the RBD antigen as compared to immunization with the non-coupled vaccine formulation (RBD + PapMV nano). Anti-RBD antibodies, generated in vaccinated animals, neutralized SARS-CoV-2 infection in vitro against the ancestral, Delta and the Omicron variants. At last, immunization of mice susceptible to the infection by SARS-CoV-2 (K18-hACE2 transgenic mice) with the RBD-PapMV vaccine induced protection to the ancestral SARS-CoV-2 infectious challenge. The induction of the broad neutralization against SARS-CoV-2 variants induced by the RBD-PapMV vaccine demonstrate the potential of the PapMV vaccine platform in the development of efficient vaccines against viral respiratory infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect